2010 Fiscal Year Final Research Report
Mechanism of PI3K activation and individualized anti-kinase therapy in gastric cancer
| Project/Area Number |
21790522
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
MUKOHARA Toru Kobe University, 医学部附属病院, 特命准教授 (80435718)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Keywords | シグナル伝達 / 個別化治療 / 胃がん / PI3K |
|---|
| Research Abstract |
Foretinib, the novel muti-kinase inhibitor, appears effective against gastric cancer cells harboring not only MET but also FGFR2 amplification. There appears inter-RTK signaling networks with MET or FGFR2 at their core in at least part of gastric cancer cells, and the networks may contribute to efficient PI3K signaling. Foretinib exerts its inhibitory effects by blocking the networks.
|
